A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study will evaluate the efficacy, safety, durability, and pharmacokinetics ofVIS‐101 administered at intervals as specified in the protocol, compared with afliberceptonce every 8 weeks (Q8W), in participants with neovascular age‐related maculardegeneration (nAMD)
Epistemonikos ID: a465abfc5e1c508b0b628c7a608b3077db3d1354
First added on: Sep 01, 2026